enGene Therapeutics Inc. updated its Corporate Presentation in July 2026, highlighting the clinical progress of its lead program, detalimogene, for non-muscle-invasive bladder cancer (NMIBC). The company expects to file a Biologics License Application (BLA) and provide 12-month data updates from the 125-patient pivotal LEGEND study Cohort 1, pivotal cohort 12-month data update and BLA filing expected in 2H 2026, and potential approval and platform designation in 2027. The company reports having $285M in cash to support these milestones. enGene Therapeutics Inc. is a biotechnology company focused on developing non-viral genetic medicines.